文献速递瓣膜病与结构性心脏病

低危二叶式主动脉瓣狭窄患者经导管主动脉瓣置换术研究

Transcatheter Aortic Valve Replacement in Low-risk Patients With Bicuspid Aortic Valve Stenosis.
PubMed 文献 · JAMA Cardiol · 2021-01-01

低危二叶式主动脉瓣研究是一项前瞻性单臂试验,纳入150例重度二叶式主动脉瓣狭窄、符合指南换瓣指征的低外科风险患者,在美国25个中心尝试植入Evolut或Evolut PRO瓣膜。30天全因死亡或致残性卒中发生率为1.3%,器械成功率95.3%,无患者出现超过轻度的瓣周漏。

要点

  • 低危二叶式主动脉瓣狭窄患者TAVR术后30天全因死亡或致残性卒中发生率为1.3%。
  • 器械成功率达95.3%,无患者出现超过轻度的瓣周漏。
  • 30天新植入永久起搏器比例为15.1%。

核心结论

  • 低外科风险二叶式主动脉瓣狭窄患者行TAVR获得良好的30天结果,死亡和卒中发生率低,器械成功率高。

研究设计与样本

  • 低危二叶式研究为前瞻性单臂试验,纳入标准源自Evolut低危随机试验,计划随访10年。
  • 共150例重度二叶式主动脉瓣狭窄且符合AHA/ACC指南主动脉瓣置换指征的患者接受尝试植入。

主要发现

  • 患者平均年龄70.3(5.5)岁,女性占48.0%(n=72),平均STS评分1.4(0.6%)。
  • 90.7%(136例)的患者为Sievers I型瓣膜形态。
  • 30天全因死亡或致残性卒中发生率为1.3%(95%CI,0.3%-5.3%)。
  • 器械成功率为95.3%(95%CI,90.5%-98.1%)。
  • 30天平均主动脉瓣跨瓣压差为7.6(3.7)mm Hg,有效瓣口面积为2.3(0.7)cm²;22例(15.1%)新植入永久起搏器。

关键数值与推荐

  • 预设主要终点为30天全因死亡或致残性卒中发生率。
  • 预设主要疗效终点为器械成功,定义为无术中死亡、1枚生物瓣膜正确定位于正确解剖位置、术后无超过轻度的主动脉瓣反流。

临床怎么用

  • 对于符合指南换瓣指征的低外科风险重度二叶式主动脉瓣狭窄患者,TAVR可作为30天结果良好的治疗选择。
  • 需关注术后永久起搏器植入风险(15.1%),并确认无超过轻度的瓣周漏。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The outcomes of transcatheter aortic valve replacement (TAVR) in low-risk patients with bicuspid aortic valve stenosis have not been studied in a large scale, multicentered, prospective fashion. OBJECTIVE: To evaluate the procedural safety, efficacy, and 30-day outcomes of TAVR in patients with bicuspid aortic stenosis at low surgical risk. DESIGN, SETTING, AND PARTICIPANTS: The Low Risk Bicuspid Study is a prospective, single-arm trial study with inclusion/exclusion criteria developed from the Evolut Low Risk Randomized Trial. Follow-up is planned for 10 years. Patients underwent TAVR at 25 centers in the United States who were also participating in the Evolut Low Risk Randomized Trial from December 2018 to October 2019. Eligible patients had severe bicuspid aortic valve stenosis and met American Heart Association/American College of Cardiology guideline indications for aortic valve replacement. INTERVENTIONS: Patients underwent attempted implant of an Evolut or Evolut PRO transcatheter aortic valve, with valve size based on annular measurements. MAIN OUTCOMES AND MEASURES: The prespecified primary end point was the incidence of all-cause mortality or disabling stroke at 30 days. The prespecified primary efficacy end point was device success defined as the absence of procedural mortality, the correct position of 1 bioprosthetic heart valve in the proper anatomical location, and the absence of more than mild aortic regurgitation postprocedure. RESULTS: A total of 150 patients underwent an attempted implant. Baseline characteristics include mean age of 70.3 (5.5) years, 48.0% female (n = 72), and a mean Society of Thoracic Surgeons score of 1.4 (0.6%). Most patients (136; 90.7%) had Sievers type I valve morphology. The incidence of all-cause mortality or disabling stroke was 1.3% (95% CI, 0.3%-5.3%) at 30 days. The device success rate was 95.3% (95% CI, 90.5%-98.1%). At 30 days, the mean (SD) AV gradient was 7.6 (3.7) mm Hg and effective orifice area was 2.3 (0.7) cm2. A new permanent pacemaker was implanted in 22 patients (15.1%). No patients had greater than mild paravalvular leak. CONCLUSIONS AND RELEVANCE: Transcatheter aortic valve replacement in low-surgical risk patients with bicuspid aortic valve stenosis achieved favorable 30-day results, with low rates of death and stroke and high device success rate. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03635424.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Forrest JK, Ramlawi B, Deeb GM, et al. Transcatheter Aortic Valve Replacement in Low-risk Patients With Bicuspid Aortic Valve Stenosis. JAMA Cardiol. 2021. PMID: 33031491. doi:10.1001/jamacardio.2020.4738

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。